PlasmaTech Announces $14.0 M Public Offering and NASDAQ Listing
New York, NY – December 24, 2014 – Press Release: New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm represented H.C. Wainwright & Co. and Aegis Capital Corp. as underwriters in PlasmaTech Biopharmaceuticals, Inc.’s public offering of 3,500,000 shares of common stock and 3,500,000 warrants. The gross proceeds from the offering were $14,035,000 and the offering price was $4.00 per share and $.01 per warrant. The warrants have a per share exercise price of $5.00 and are exercisable immediately. PlasmaTech common stock and warrants began trading on the NASDAQ Capital Market (effective December 19, 2014) under the symbols “PTBI” and “PTBIW” respectively.
PlasmaTech Biopharmaceuticals, Inc. is a biopharmaceutical company focused on advanced targeted treatments for critical patient care. The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey J. Fessler and Marcelle Balcombe.
- Sichenzia Ross Ference LLP代表Aegis Capital进行Farmmi，Inc.的4830万美元承销公开发行。 - May 3, 2021
- Sichenzia Ross Ference LLP在與私人配售有關的投資者訴訟中在第二巡迴上訴之前勝訴 - April 30, 2021
- Sichenzia Ross Ference LLP代表美国电池金属公司进行1,500万美元的注册直接发行 - April 29, 2021